Introduction
What health insurance should cover and pay for represents one of the most complex questions in national health policy. In countries that finance health care in whole or in part through third-party health insurance, coverage design provides the basic architecture that guides the flow of funds throughout the health care system, designating which services and procedures will be paid for, and which will not. The health insurance coverage framework thus heavily influences the extent and scope of health care, the duration of care, and the settings in which health care will be provided.
The United States and Israel have health systems that are fundamentally similar in many respects, including their shared decision to rely on private insurance (i.e. non-governmental), both for profit and not for profit. At the same time, however, the two nations have taken a strikingly different approach to the question of what health insurance should cover and who gets to decide questions of coverage. In Israel, the power to decide what gets covered rests squarely with the central government.
In the United States, social and cultural preferences have been quite deliberately built into the fabric of US law, with respect to both constitutional structure and the vast fabric of laws enacted in furtherance of this structure. As a result, the design of private insurance rests on a complex and intricate power-sharing arrangement across three principal decision centers: (1) the federal government, to which Congress, acting under its constitutional power to regulate commerce, has assigned expanded authority over health insurance, including its design; (2) state governments, which under longstanding US traditions and constitutional principles of federalism, and the laws enacted there under, continue as the primary regulators of health insurance (but now within new federal parameters); and (3) the health insurance industry itself, to which much deference continues to be accorded. To this diffuse power arrangement, in which no single entity holds definitive sway, must be added perhaps the most defining aspect of American culture, what Mark Twain, arguably the nation’s greatest philosopher, termed the collective desire perpetually to ‘light out for the territories’ (Twain, 1885). Where no one has the power to decide, the illusion of individual freedom tends to hold particular sway, and there is resistance to any ‘one size fits all’ solutions.
This power-sharing arrangement within the United States has long been evident in the wide coverage variation found across the more than one million employer-sponsored health plans that are governed by the federal Employee Retirement Income Security Act (ERISA), which vests immense powers in employers and their insurers and plan administrators to decide what will be covered and how much (Rosenbaum et al., 2012).
This tradition has continued under the regulated individual health insurance market established under the Affordable Care Act (ACA) including the tax-subsidized health plans sold to eligible policy holders though the exchange system (known informally as the health insurance marketplace) created under the law. As a result, both the broad contours and the essential details of coverage can vary significantly from state to state, and, potentially, between market to market within a single state (Rosenbaum et al., 2012).
This national orientation within the United States toward a structural diffusion of regulatory powers, which always has been a hallmark of its health care system, may grow even stronger. After dozens of attempts by a hostile Congress to repeal the ACA in the wake of its passage, a watershed election in 2016 brought to power a Republican President and strengthened Republican Congress dedicated to ending what are perhaps the ACA’s two most basic reforms: the elimination of insurers’ ability to refuse or price coverage based on health status; and a guaranteed of a minimum level of coverage – pegged to plans sold in the workplace – for policy holders in the individual and small-group markets. Should the repeal effort ultimately succeed, states once again will face full-bore the question of what type of regulatory framework should govern policies sold within their borders and will grapple with this problem stripped of the federal tax penalty incentives crucial to encouraging healthy people to buy health insurance and the hundreds of billions of dollars in federal subsidies crucial to making the tax penalty fair by making the cost of coverage feasible for those without access to subsidized workplace benefits. How to tackle the question of benefit design in such a fundamentally altered policy environment will represent an enormous test for the states.
The Obama Administration, deeply aware of the tensions that come with power diffusion, delicately sought to introduce a very modest level of standardization into its federal regulatory framework, but – the claims of repeal advocates notwithstanding – its attempts to do so only nibbled around the edges of immense challenge. For example, the ACA itself established a relatively detailed and comprehensive preventive coverage standard for all health plans permitted to continue after the law’s effective date. With respect to the ACA’s federal regulatory framework for coverage known as essential health benefits (EHB) the law leaves broad discretion to individual states, preserving their authority to regulate the precise content of insurance; the Administration honored this approach, leaving the major details of benefit design to state governments. Furthermore, states themselves, in their regulatory approach to the sale of insurance, tend to leave crucial aspects of coverage design to insurer discretion, thereby enabling insurers to determine the precise parameters of coverage.
Should the Trump Administration and Congress succeed in repealing the EHB standard, the task will once again fall solely to states to define coverage in the individual and group insurance markets. This task comes at a time when, increasingly, the United States is focusing on the concept of ‘value-based coverage’ as a means of promoting greater health care quality and controlling the cost of health insurance. While the move toward value-based coverage is often portrayed as being based on apolitical grounds, such as evidence based medicine, or individual preferences, issues of health care access inequality are likely to arise, making the question of what the nature and extent of coverage should be a matter of politics and ethics. It is this realm that the Israeli case is relevant for the United States, regardless of whether the ACA EHB coverage standard survives or the nation abandons the idea of a broad national coverage framework for private health insurance and returns the whole question of coverage to the states (Rosenbaum et al., 2012).
Israel, has exercised a close hold on basic coverage, maintaining strong controls over health care spending. This approach more closely resembles that found in other wealthy democracies with national health systems that rely on government budgets or health insurance to finance care. For example, Sweden, the Netherlands and New Zealand have sought to define a ‘core benefits package’ and/or ethical criteria for deciding what will be covered by public health insurance. Australia and New Zealand take a more explicit approach to pharmaceutical coverage, employing mechanisms for inclusion and exclusion of specific pharmaceuticals via a government-administered formulary approach in the context of their public health insurance arrangements. In the United Kingdom, the National Council for Clinical Excellence plays a major role in using cost effectiveness studies to mandate (or in the more recent regime strongly recommend) coverage of specific health care treatments under its National Health Service. In the social health insurance schemes of the Netherlands, Germany and Switzerland, sickness funds are mandated to provide a defined list of health services and treatments (Chinitz and Israeli, Reference Chinitz2010; Mossialos et al., Reference Levitt, Cox and Claxton2016).
Israel has a very explicit, detailed definition of benefits and coverage (Kaplan and Baron-Epel, 2013; Rosen, 2015). This approach has been surprising, perhaps, because health care is so highly valued by the Israeli population Nonetheless, under Israel’s national health insurance system, entitlements are listed in a highly detailed way, in many cases going as far as to delineate the indications for use of covered pharmaceuticals. Israel’s approach to determining the parameters of coverage contrasts deeply that found in the United States, underscoring how much national values, cultural norms and differing social structures, as well as key differences in the health care systems – rather than clinical considerations alone – shape what it means to have insurance coverage.
In this article we compare the US approach, with its deep roots in federalism and deference to industry, with that taken by Israel. Differences in size, political system and culture inevitably impinge on any such exercise, not to mention the issue of United States ‘exceptionalism’ and reticence to learn from abroad. Yet the similarity in the two nations’ reliance on private insurance makes such an exploration of who decides coverage a valuable and instructive one. As the US deals – as we have argued it inevitably will need to and regardless of Republican efforts to repeal and replace the ACA – with the problem of benefit standardization, the Israeli experience may offer important lessons and insights. Our analysis is probably most relevant to the state-based private insurance markets created by the ACA, as the notion of ‘qualified plans’, providing standardized benefits, was central to that context. However, there is also relevance to the National Coverage Determinations of Medicare, and state-level decisions regarding Medicaid, such as the Oregon Plan or Medicaid expansions in various states, such as Indiana, where Vice President elect Mike Pence was governor.
We first present the concept of coverage design and how the basic benefit package are determined under Israel’s national health insurance system. We then discuss the evolution of US coverage policy under the ACA, from the terms of its original enactment through what, by 2016, had become multiple rounds of regulatory implementation of the original terms of the law. We conclude with a discussion of the nature of the two national approaches and suggest lessons for both countries that emerge from this comparison.
Israel’s approach to defining the extent and scope of health insurance coverage under its national health system
Israel is a small nation. In geographic terms it covers an area about the size of Connecticut, while its population in 2016 stands at about 8.5 million (Central Bureau of Statistics, Reference Twain2015). And yet within its borders Israel remains incredibly diverse, with substantial political polarization around matters of both domestic and foreign policy. While, from outside, the country may seem like a unified, almost militarily cohesive entity, the political scene is fractious. In most policy areas consensus is hard to come by. In this regard, the health system is somewhat unique in terms of the broad support it appears to have among the Israeli public and across political parties.
As described elsewhere (Chinitz, 1995) in the early 1990s Israel’s economy, as many others, embarked on a neo-liberal path that disrupted previous linkages between health policy and party politics. Ironically, this led to explicit empowerment of a government body to set the precise limits of coverage on behalf of an entire population.
In 1995, Israel’s national health insurance underwent major reform. Previously, every resident could choose among four health plans, each of which offered a variable range and level of insurance coverage. Beginning in January 1995, Israel implemented a national health insurance scheme covering all residents. Israel’s plan is both universal – all residents, regardless of ethnicity – and egalitarian. Everyone is entitled to a uniform and standardized level of coverage (known as a basket of services) offered by each of the four health plans (health plan issuers also may offer supplemental policies covering items not included in the standard basket, as well as a broader choice of health care providers). To pay for this basket of services, the health plans receive government allocation in the form of risk-adjusted capitated payments intended to cover the anticipated costs of covering their insured populations. Contrary to some perceptions, this makes the health plans not just deliverers of health care, but also insurers carrying out the government’s guarantee of coverage within their capitated budgets.
The starting point for the basket of health services, as established in the law, was taken from Clalit, the largest health plan in the pre-reform Israeli market, which at the time of enactment insured over 63% of all residents and which remains the most popular plan today (with 52% market share). Under reform, the four health plans would be expected to provide the identical basket to their members. However, despite the fact that Clalit represented the practical coverage norm given its market penetration, the road to implementation was hardly smooth.
To begin with, the three other health plans were opposed to the mandatory adoption of the Clalit basket, since each offered its own particular coverage design that it judged as being attractive to its members. For example, the basket of Maccabiee Healthcare Services was broader than Clalit’s plan. During an April 1993 meeting with the Knesset’s Joint reform oversight committee, both Maccabee and Meuhedet Health Services (another popular plan) expressed their fears over how their members would receive the information about scaled back services. On the other hand, both insurers understood that under the law’s payment terms, they could not continue to offer the same basket of services (the cost per person for Clalit’s basket was New Israeli Shekels (NIS) 1300; the cost per person for Maccabis basket at the time was NIS 1650), in effect, the law’s approach to pricing coverage in turn led to fundamental changes in coverage design within the relatively generous plan of Maccabi. This convergence to some kind of ‘average’ level of coverage was crucial to the successful implementation of National Health Insurance (NHI), and implies satisfaction with a universal decent minimum of coverage, which better off populations must be subject to, even if previously they had ‘better’ coverage. This point is very salient to the US context, in which such an orientation, while tentatively broached by policies such as the tax on so called ‘Cadillac’ health insurance plans, is not consensual. Thus, the Ministry of Health was tasked with the responsibility of constructing what ultimately became a basket of coverage fixed in law, with the spirit of the emerging NHI law encouraging very detailed coverage policies. Without any precedent for such an endeavor, the Ministry lacked a formal organizational rubric that could be assigned the task. Nonetheless, a process emerged that drew on a number of available resources, as described next.
The time pressure under which the Ministry of Health was forced to work as part of the legislative process meant that some of the technologies included in the basket remained unclearly defined. The case of coverage for genetic testing offers an example of the challenges of preparing detailed technology terms. Genetic testing was included under a broad coverage parameter that stated simply that covered individuals would be eligible for ‘genetic consultation for genetic illnesses including blood tests’ (NHI Law, Reference Rosenbaum, Mehta, Dorley, Hurt, Rothenberg and Lopez1994d). But because the parameters of Clalit’s detailed terms of coverage already were considerably narrower than technology and medical practice dictated at the time of enactment, the legislation was followed by a post-enactment policy directive from the Health Ministry that broadened the scope of coverage through explicit language that not only set the coverage baseline in specified terms but also provided for the updating of genetic testing coverage in accordance with specified criteria (NHI Law, Reference Rosenbaum, Mehta, Dorley, Hurt, Rothenberg and Lopez1994d). This reflects a natural inclination, at least on the part of Ministry of Health, to establish an ‘up-to-date’ basket of services as the starting point.
While, as mentioned above, financial viability was a key element of the process of implementing the NHI law, the budgetary implications of this type of ‘fine tuning’ expansion of the Clalit parameters was not explicitly addressed legislatively. Instead responsibility for baseline and updating within stated expenditure limits fell to the implementation process. We return to this aspect below.
Adjusting the basket
Once the initial legislative basket was established, the task became how to update it to take evolving medical technologies and procedures into account. For this reason, as might be expected, the law stipulated both financial and technological adjustments over time, as well as the process by which these adjustments would happen.
In financial terms, the law states (Ministry of Health, Reference Enthoven2016) that the cost of the basket is to be adjusted annually at the rate of increase under Israel’s index of medical costs. This index is composed of several different measures (on the wage of a salaried position inside and outside the medical system, on the consumer index, and on the index of construction inputs), and is meant to reflect the changes in the price of technologies, but has typically been seen by health sector stakeholders as inadequate to meet the needs of a growing and aging population. The law also addresses the mechanism for adjusting the basket of services (NHI Law, Reference Mossialos, Wenzl, Osborn and Sarnak1994a) whether by adding or removing items. This adjustment authority lies with the Minister of Health and is contingent on approval from various parties in the government or Knesset.
For the first three years of the law, there were no annual adjustments to coverage, except for a handful resulting from high profile suits brought by patients denied coverage. Only in 1998 was the first overall adjustment made with the introduction of 13 oncological medications. This followed media pressure on the part of cancer patients including a young girl’s televised request not to let her die. As a result, the Minister of Health decided to establish a committee to decide which technologies would enter the basket. The committee was to make recommendations to the minister and in 2005, by government decision, the structure, composition and work patterns of the committee were anchored.
The committee convenes every year to discuss the list of potential technologies for the basket. Of the various technologies, the committee is to determine which new ones to introduce under the state-set budget. The budget that is determined by the government before the committee begins its work. The adjusted amounts, during the years, ranged from NIS 0 to 450 million NIS (Plotnik and Keidar, 2015).
Budgeting and financing the basic basket
A key element of the 1995 law was that the actuarial commitments of the health plans be matched by adequate funding. In other words, the expectation was that government commitments to coverage had to be explicitly matched by willingness to allocate specific, earmarked, budgets.Footnote 1
To finance services for the eligible population, the legislation specifies that all residents must pay a payroll-driven health tax amounting to 4.8% of their earnings. These payments are designed to cover the expenses of the basket, and revenues collected are distributed among the health plans on a capitation basis (NHI Law, 1994c). These payments do not cover the full cost of the health basket; the state must add general budget funds to finance the legislation (NHI Law, 1994b). In recent years, this public supplement (akin to the general revenue payments by the US Congress that support of Medicare Part B and thereby supplement the cost of Medicare Part A, whose funds are derived from a special payroll tax) amounted to 300 million NIS (about $70 million annually, specifically for new technologies. Beyond this, the budget is increased by the index mentioned above, intended to reflect inflation, although health sector advocates typically argue that specific health sector price inflation is not adequately accounted for by the index.
In sum, in 1995 the Israeli government in effect nationalized a pre-existing system of competing health plans, introducing the following provisions and regulations intended to make the health insurance system universal and equitable. Under the system, health insurance became universal and mandatory. The eligible population became entitled to a standardized level of basic coverage that in turn was based on the list of services of one health plan, that was mandated to be provided by all four health plans. In addition, a detailed and elaborate mechanism for adjusting the standard basket was established, with financing over time predicated on a risk-adjusted capitation whose costs would rise as the anticipated cost of the standard basket rose. This mode of operation has withstood inevitable controversy over both the medical adjustment index and the annual allotment for adding new technologies to the basket of services.
Obviously, not all new technologies will enter the basket. This means that patients do not always receive the medications they require – some pay out of their own pocket to obtain them, others dispense with treatment and all that this entails. And yet at the same time, public opinion surveys suggest a fairly high degree of consensus around the need for difficult choices. One study (Kaplan and Baron-Epel, 2013) showed that the public accepts the necessity of tough decisions and, on the whole, supports the ministry’s management of the basket of services. Other surveys show public support for prioritizing investments in the early detection of illness and in the care of frail elders, support for broadening coverage for disadvantaged populations, for example to strengthen the cultural competence of health services as well as public preference for treatments improving quality of life over prolonging life (Chinitz et al., Reference Chinitz and Israeli2009).
Currently, attention has been focused in government circles and in the media on the fact that the annual budgetary increment for updating the standard basket of health services has declined from 1.5% of the total budget of the health plans to 0.7% as of 2014, and that too many new technologies, especially expensive cancer, drugs are being left out of the basket. The solutions under debate include increasing general revenue spending or permitting the inclusion of life saving cancer drugs in the supplemental insurance policies. Some claim that this reflects the breaking point of the health basket updating process. Yet the evidence suggests that the institutional elements that have evolved as the mechanism for implementing the NHI – including a defined basket with a guaranteed budget, an updating process for adding new technologies, and the safety valve of supplemental insurance – will continue to function as the means of defining EHB. While the establishment of a national health insurance system could not and did not eliminate all conflict and controversy regarding coverage determinations, it has succeeded in creating an institutional framework up to the task of addressing the difficult challenge of both determining initially what should be covered as a nationally guaranteed benefit and of determining and updating that determination as technology, medical norms and cultural preferences evolve.
The US experience
The ACA and EHB
At the outset, it is important to clarify the fundamental nature of the Patient Protection and Affordable Care Act (ACA). Unlike Israel’s uniform national health reform scheme, the ACA did not displace prior coverage law through detailed, preemptive federal standards. Instead, responding to the cultural, constitutional and legal framework of the United States, the ACA law is designed to take what might be thought of as an interstitial approach by building out the previous, highly pluralistic coverage regime.
This pluralistic regime consists of numerous separate bodies of laws governing health insurance and employer-sponsored health plans. Employment-based coverage continues to dominate the working-age population, and plans offered by private employers continue to be governed by the ERISA (29 U.S.C. § 1001 et seq.). Although ERISA does require coverage of a handful of treatments and procedures (including the preventive services coverage mandated by the ACA for most forms of health insurance) (29 U.S.C. § 1181-1185d), ERISA continues to give larger employers, as well as employers of any size that self-insure their plans, wide latitude over what they will cover (PPACA § 1563). Similarly, public employee plans continue to be regulated by the laws that establish them, with larger plans continuing to be free to design their benefits. Medicaid, the shared federal/state public insurance program for the poor and medically vulnerable, continues give states considerable discretion over coverage for their traditional populations. Medicaid also gives states the option whether to extend eligibility to all low income adults as a result of the United States Supreme Court’s 2012 decision in National Federation of Independent Businesses v Sebelius striking down the law’s intended expansion for poor adults as an unconstitutional mandate (124 S. Ct. 2566). Medicare continues as a federally administered, federally regulated public insurance program governed by its own benefit design rules.
Still, the ACA contained revolutionary provisions whose purpose is not only to create affordable and accessible insurance for people who previously lacked it but also to strengthen and improve the quality and scope of coverage in the redesigned individual market as well as the small-group market. This second aim is captured in the ACA’s ‘EHB’ standard, which was a response to evidence of pervasive coverage gaps, limits and exclusions in policies sold to individuals (Pollitz et al., 2001) and small groups (IOM, 2012).
The ‘EHB’ requirement applies to two distinct private markets and one public insurance market. First, the definition applies to the ‘small-group’ market of ERISA-governed employer-sponsored health plans in the case of plans that cover ‘small’ groups (defined as 50 full-time employees or fewer except in states that opt for a higher cutoff up to 100 full-time workers) (Protecting Affordable Coverage for Employees Act, Pub.L. 114-60) that do not self-insure. Although insured employees in the United States are more likely to work for larger firms and firms that self-insure (Claxton, Reference Chinitz, Meislin and Alster-Grau2008 [Reference Chinitz, Meislin and Alster-Grau2002]) the small-group insurance market accounts for about 15% of the US population.
Second, the EHB standard applies to policies purchased in the individual insurance market, including ‘qualified health plans’ sold to eligible people on a subsidized basis through the health insurance marketplace (PPACA § Reference Plotnik and Keidar1302) who are seeking an affordable private insurance alternative because they lack either employee benefits or eligibility for public insurance (Gunja et al., Reference Grace, Noonan, Cheng, Rubin and Rosenbaum2016). As of July 2016, ~11.1 million people were insured through marketplace plans, and about 85% of those with marketplace coverage received subsidies (Center of Medicare and Medicaid Services, 2016). Another several million people obtain coverage through individual policies sold outside the marketplace (Levitt et al., Reference Kaplan and Baron-Epel2016), although many of these plans are covered by grandfathering rules that allow them to maintain an ACA-non-compliant benefit design through the end of calendar year 2017 (Counihan, 2016).
Third, the EHB standard applies to the adult Medicaid expansion population, whose numbers surpassed 9.6 million people by June 2016 according to the federal government (USDHHS/CMS, 2016). The EHB standard is both more and less generous than traditional Medicaid coverage standards. About one out of every six Medicaid enrollees is a newly eligible adult now included because of Medicaid expansion (states can and do supplement the EHB coverage floor with additional, traditional benefits) (Rosenbaum et al., Reference Rosen2016).
In sum, the EHB statute reaches the small-group insurance market, the individual private insurance market and the Medicaid expansion market. In 2011, the Institute of Medicine (IOM) estimated that by 2016, ~68 million people would be enrolled in a form of health insurance subject to its terms (IOM, 2012), elevating the importance of the EHB standard.
What makes the EHB standard so potentially far-reaching is that it is positioned to set a federal minimum coverage standard for state-regulated private insurance sold in the individual and group markets that previously lacked such a floor. Under constitutional principles of federal preemption, this coverage floor thus implicates a vast body of state insurance laws that regulate the individual and small-group insurance products. Furthermore, the EHB statute, while confined to a relatively small slice of the employer market, represents a marked departure from ERISA law and custom, since it potentially raises the standard of coverage in the small-group market. The EHB standard thus presents a major policy issue: To what extent should federal law displace the primacy of state insurance regulatory laws, including the prior body of state law governing the individual and small-group markets? It also raises substantive policy issues of which benefits should be included as EHB.
Implementation of the EHB standard
Implementing the EHB coverage standard has meant confronting several distinct challenges. The first is how much to displace state laws that impose a lower standard. This challenge in turn raises both legal and political concerns given the pull of the federalism tradition. The second challenge is financial. Too broad an interpretation of the provision raises the cost of coverage, and while health insurance subsidies in the marketplace constitute an open-ended legal entitlement, the focus on keeping the cost of public subsidies down is as intensive as it is with Medicare and Medicaid. The question has become how to advance this regulatory foray into the meaning of insurance coverage while maintaining cost controls and finding a way to reconcile the EHB standard with a blizzard of variable state laws.
The course of implementation, which was delegated to the Secretary of the United States Department of Health and Human Services (HHS) begins with the legislation itself, which is a mass of inconsistencies and contradictions. The statute directs the HHS Secretary to ‘define’ EHB. In doing so, however, the law not only sets forth 10 broad benefit categories but also directs her to address ‘the items and services’ within each covered category. In other words, the Act establishes 10 coverage categories and then instructs the Secretary to define – at a specific ‘item and service’ level – what will be covered within each category. Furthermore, the statute bars the Secretary from using coverage standards, benefit design standards, payment standards or payment incentives that discriminated in coverage on the basis of disability or expected length of life. Taken together, these requirements appear to amount to a national legislative directive to the HHS Secretary to establish a nationally uniform, granular coverage standard that displaces not only broader and potentially vaguer state laws but also the discretion of insurers to decide, within any broad coverage category, exactly what treatments and services they will cover.
At the same time however, the ACA, and its specific EHB coverage standard, established two crucial caveats. Both of these caveats ultimately would exert strong practical and political pressures on the federal implementation effort. The first caveat was preservation of state primacy to regulate health insurance. This primacy could be read as extending only to insurance markets not superseded by the EHB standard. But read to its fullest extent, the preservation of state powers could be interpreted as a cautionary light governing how far HHS should go in implementing the standard. Furthermore, because state insurance laws are so variable, this decision to rest the ACA atop state insurance law virtually meant that somehow the standard had to be reconciled against highly variable coverage requirements. This variation is not only from state to state; additionally, states vary in the level of regulation they apply to distinct markets, with stricter rules for the large group insurance market and more relaxed rules in the smaller and less stable small-group and individual markets.
The second caveat – and one reminiscent of the Clalit point of reference in Israel’s health reform experience – is the requirement that in defining coverage, HHS is expected to adhere to the coverage standards reflected in a ‘typical employer plan’ [PPACA § 1302(B)(2)(A)]. The law offered no definition of what a ‘typical employer plan’ consists of, other than 10 essential benefit coverage classes (ambulatory patient services, emergency services, hospitalization, maternity and newborn care, mental health and substance use disorder services including behavioral health treatment, prescription drugs, rehabilitative and habilitative services and devices, laboratory services, preventive services and chronic disease management, and pediatric services, including oral and vision care) [PPACA § Reference Pollitz, Sorian and Thomas1302 (b)(1)] (as it would turn out, at least two major benefit classes – habilitation and pediatric-specific benefits – were not features of ‘typical’ employer plans, an obvious contradiction). Beyond lacking a definition of the employer benchmark, the legislative language of the ACA also overlooked the fact that the scope and depth of coverage in terms of the range of benefits offered may differ significantly depending on whether the employer is large or small.
Added to the vagaries of the EHB statutory terms is another crucial aspect of coverage in the United States – cost sharing. Because the cost of health care is so uncontrolled (Frankford and Rosenbaum, 2017), private health insurance has eroded substantially and now includes sizable deductibles that vary by plan design, as well as elaborate copayment and coinsurance requirements that vary with the type of treatment and the setting of care. Not only do Americans bear the full cost of uncovered treatments, items and services, but depending on whether their covered services are delivered ‘in network’ or ‘out of network’ their direct financial obligations also can vary and can be quite substantial.
The ACA did not eliminate this problem; indeed, it effectively locked the problem into law by sanctioning the use of substantial cost sharing in health plans, including those sold in the marketplace. This sanctioned use is expressed in ‘metal tiers’ tied to actuarial value. The standard silver plan, to which marketplace subsidies are tied, must achieve an actuarial value (the amount of premium allocated to payment for covered claims) of 70%. Plans can have actuarial values as low as 60% (bronze plans) and as high as 90% (platinum plans). The law does set upper limits on deductibles that are tied to the permissible deductibles used in the high-deductible health plan market [PPACA § 1302 (c) (3)]. But in 2016 this upper limit exceeds $6500 for an individual and $13,000 for a family (Internal Revenue Services, 2016). Within this stew, the ACA permits insurers to design their own cost-sharing rules, as the resulting design is considered non-discriminatory on prohibited grounds (although federal standards are vague on what would be considered discriminatory) (C.F.R. § 92.207).
HHS was thus expected to wade into this confusing and contradictory set of Congressional directions: establish the rules of coverage but follow (undefined) employer plan parameters; exercise preemptive controls but reconcile those controls with federalism principles and state regulatory primacy; move toward uniformity but respect the discretion given insurers to come up with their own Byzantine cost-sharing rules. In doing so, HHS turned for help to the United States Department of Labor, which regulates ERISA plans of all shapes and sizes. As it turned out however, and again reminiscent of the Clalit problem, even the Department of Labor could not say with any certainty what is covered under a ‘typical’ employer-sponsored health plan. A report entitled ‘Selected Medical Benefits’ prepared for HHS by the Labor Department in 2011 (Labor Department, Reference Saltman and Figueras2011), used information from the Bureau of Labor Statistics to try to answer the ‘typical’ question. Based on data from a representative sample culled from 36,000 employers, the study relied on plan summaries filed annually with the agency, which provide only the most cursory overview of coverage. For example, while the report indicated that 99% of plans from the most recent survey years covered hospital room and board with 92% requiring some level of patient cost sharing, the report lacked the type of details needed to arrive at what might be thought of as a national coverage standard.
The limited information from the Labor Department was further complicated by the fact that, as noted, several EHB service categories and sub-categories had no counterpart in the employer market; thus, there was no real frame of reference. For example, the habilitative service sub-category had virtually no counterpart under typical employer plans. Indeed, the Department of Labor 2011 report made absolutely no mention of habilitative services. Furthermore, while about half of all states now mandate coverage for habilitative treatments for children with autism, others do not, and many types of developmental conditions remain unaddressed entirely under state law. Other EHB coverage categories, such as pediatric services, simply are not recognized as a distinct coverage category under typical employer plans, other than, perhaps, for well-child exams; if references to pediatric coverage appear at all, they tend to do so as expressed exclusions of behavioral health treatments for children that are educational in nature (Grace et al., Reference Frankford and Rosenbaum2014). Indeed, the 2011 DOL survey showed that only 70% of plans explicitly provided for such coverage (a not-unexpected result given both the tendency of plans to describe coverage in general terms (e.g. inpatient care, medical care) (Labor Department, Reference Saltman and Figueras2011).
In sum, HHS was tasked with modeling a national coverage design based on a ‘typical’ employer plan that, as it turned out, either did not exist or else could not be described with particularity. Furthermore, the agency also had to reconcile benefit design with an actuarial standard (similar to the Israeli tradeoff between coverage and financial viability of the system) well below the typical employer plan (70% rather than 80%) (The United States Department of Health and Human Services, Assistant Secretary for Planning and Evaluation, 2011) for all but the lowest income purchasers who qualify for substantial cost-sharing assistance as well as premium subsidies. Keeping coverage affordable in the world’s most costly health system thus became an issue of paramount concern, particularly since the working assumption was that initial enrollees would be more likely to have serious health problems, thereby affecting the financial viability of the insurance market (Donohue et al., Reference Counihan2015).
Regulatory implementation of the EHB coverage standard
Faced with these contradictions, and with limited help available from the Department of Labor, HHS turned to the Institute of Medicine (Subsequently renamed the National Academy of Medicine in 2015), a Congressionally established scientific body that undertakes health policy-related studies on behalf of the federal government and others. The charge to the IOM, which delivered its report in 2011 (full publication came in 2012) was not to define the specific benefits and services that should be included in the EHB package, but to provide guidance on ‘policy foundations, criteria and methods’ the Secretary should consider in establishing and later updating coverage in light of both the 10 required coverage classes and the directive that she reference the ‘typical employer plan’ in doing so. In so doing, the study committee was to assess insurers’ approaches to the question of coverage (in particular the question of medical necessity), as well as approaches in aligning the terms of coverage with other aspects of the law, including its non-discrimination requirement.
Reflecting the fundamental thrust of the EHB statute – to create a nationally uniform benefit design that reflected a typical employer plan and balanced a wide range of interests – the IOM recommended a national benefit design tied to premium spending benchmarks that reflected the contours of a typical employer package, as identified by the IOM through extensive review of employer plans and approaches taken by major insurers. In effect, the IOM recommended a strategy strongly reminiscent of the Israeli approach, that is, a set expenditure target tied to broad coverage terms, with discretion for insurers to interpret the terms of coverage and with the broad standards updated regularly. As for states, the IOM envisioned a role in which states were tasked with testing alternative approaches to coverage for specific conditions and treatments. In other words, the IOM came down on the side of a unified, preemptive federal approach.
Although HHS’ ultimate approach to implementation surprised many but made basic sense given the confusion of the legislative language itself, the political and constitutional tensions, and the need for a pragmatic solution that could move the nation toward full implementation of a benefit design affecting nearly 70 million people (Bagley and Levy, Reference Bagley and Levy2014).
In December 2011 – with time getting short (insurers would need years to develop, price and obtain federal and possibly state approval for their benefit packages, which had to be ready for sale on the Exchange by the fall of 2013) and before the IOM report was finalized – HHS issued a coverage bulletin (HHS Essential Health Coverage Bulletin, Reference Gunja, Collins, Doty and Beutel2011) that amounted to a full-blown rejection of the IOM vision of national uniformity that combined broad and preemptive coverage terms with discretion to insurers and actuarial values. Instead, HHS opted for an approach under which each state would set its own EHB ‘benchmark’ plan in accordance with selection rules designed to ensure that state selection would focus on its most popular plans. If a state did not select (and many, resisting the law, threatened not to do so), then the federal government would select the state’s most popular small-group plan. Each state (or the Secretary in the absence of state action) would then be expected to adjust its benchmark in order to conform its design to the 10 EHB coverage categories (e.g. adding in habilitative benefits or pediatric vision and oral coverage). States were given guidance on how to define pediatric oral and vision care as well as habilitative services, all of which were likely to be absent from underlying state insurance regulatory schemes.
In sum, the federal standard effectively became a federally adjusted state standard, leaving in place the coverage variability among the states while raising the overall terms of coverage to a minimum federal level reflecting the 10 broad EHB classes. The final formal regulations, issued in 2013 months before enrollment began echoed the Bulletin. Later policies would very slightly refine this approach but only around the edges. For example, subsequent policies required parity (i.e. broad equality in terms of quantitative limits) between habilitative and rehabilitative services (C.F.R. § 156.115) and offered a more unified approach to defining the term. But as implemented, the federal EHB framework operates in the interstices of state law rather than comprehensively supplanting it.
In the 34 states that as of 2016 rely on a federally administered health insurance marketplace rather than establishing their own exchanges (Kaiser Family Foundation, 2016), the federal government has been willing to be somewhat more directive. Thus, its 2017 plan year issuer letter, which offers policy guidance to issuers selling marketplace plans (United States Department of Health and Human Services, Centers for Medicare and Medicaid Services, Center for Consumer Information and Insurance Oversight, Reference Claxton2016) encourages issuers to sell more standardized cost-sharing options in order to enable consumers to draw more meaningful distinctions among coverage design. But the federal marketplace continues to rely predominantly on the health plans licensed for sale in that state, with only limited federal adjustments to reflect the broadest contours of the EHB statute. In effect, the combined pressures of federalism, affordability, legislative confusion and the politics of US health policy has meant that – despite legislative language that could have legally supported a more robust federal approach similar to that found in the Israeli system – the Obama Administration chose a practical approach. Recent developments suggest a slightly greater federal willingness to intervene in coverage design, at least insofar as encouraging a more standard approach to patient cost sharing is concerned. But the federal role is one of light steering rather than dominance.
Discussion
US traditions make a unified approach to problems as complex as health care financing and coverage exceedingly difficult – indeed, so difficult that even where Congress seemingly grants the Executive Branch the authority to act in a nationally uniform fashion, the grant of power ultimately gives way to practical solutions that reconcile the terms of law to actual observed conditions. And even the modest standardization sought under the ACA ultimately may give way to a further fracturing of power to define coverage. From a constitutional powers perspective, Congress, exercising its power to regulate commerce, certainly could have drafted a law that superseded state insurance law. It chose not to do so even at the height of support for the ACA, and now it is moving in precisely the opposite direction.
And yet, more recent developments in the articulation of EHB parameters suggest a somewhat growing willingness to confront the problems of ambiguity and variation in coverage. The Obama Administration’s attempt to move toward more standardized coverage, at least in the individual and small-group markets, received some added boost from the urgency of addressing the need for standardization as a mechanism for greater transparency in coverage and – indirectly at least – cost containment in order to begin to target payment on treatments that work. Even conservative US lawmakers have recognized the problem of coverage limitations and exclusions under private plans, introducing legislation to incentivize more appropriate coverage, such as legislation that permits tax-favored health plans to maintain their tax status while at the same time eliminating the large deductibles required under such plans that in turn impede access to effective treatments for people with serious and chronic health conditions (Bevan and Brown, Reference Bevan and Brown2014). While such legislation is hardly to be equated with Israel’s precise, government managed approach to coverage design, it is evidence of the degree to which lawmakers in the US recognize the health and health care implications of poor coverage design and seek to drive more rational coverage decisions.
It is unclear whether even the minimal standardization promoted by the EHB statute will survive. It could be that the entire question of minimum coverage standards ultimately will be returned to the states, from whence it began during the long and arduous journey that ultimately concluded with passage of the 2010 law. But regardless of whether EHBs survive as a federal coverage minimum, states play the predominant role in defining and delimiting coverage in the individual and group insurance markets. This role is preserved in the EHB legislation.
Whether part of the federal policymaking fabric or again returned to the states, the United States may benefit from the Israeli experience, which highlights three distinct elements of the EHB determination process: first, selection of a starting point for defining coverage, by identifying an average plan either on a state or nationwide basis; second, formulating the expected cost of EHB coverage; and third, creating a mechanism for updating EHB within a budget. This approach is essentially the vision found in the IOM study, and it has produced high-quality coverage with modest cost sharing in Israel. Of course, to be truly effective, the same approach would have to be applied across private US insurance markets as a whole; otherwise, the threat of provider non-participation would be significant. For this reason, unlike Israel, the varied US system is more likely to yield a variety of ‘basic baskets’ and associated expected costs, for example, increasingly specified versions of the four metal typology of health plans currently on the shelf for choice by US citizens on the exchanges (Enthoven, Reference Donohue, Papademetriou, Henderson, Frazee, Eibner and Mulcahy2014).
The United States may never have the type of panel or committee operating in Israel to update the basket of services at the national level, but it is feasible that individual states could pioneer such an approach; indeed, the origins of the ACA lie in the experiences of a single state, whose governor and legislature forged ahead with a practical plan that has turned out to work exceedingly well.
In this regard, should the EHB provisions of the ACA survive, the ACA also contains special state innovation waiver authority that could be used to enable individual states to test innovations in health insurance design that move away from standard EHB coverage rules. For such waivers, the Israel experience becomes highly relevant, and as of 2016 it appears that at least one state may be moving in the direction of greater coverage uniformity.
At the same time, it may be that Israel can learn from the US case. In Israel, what room there is for expression of consumer preferences in health insurance is left to the supplemental and commercial health insurance markets. As clear as governance of the standard basket under NHI has been in the Israeli case, regulation of the supplemental and private markets, and especially the interaction between them, has been lax and ineffective. A large percentage of citizens hold both types of insurance without being well informed of their contents and coordination of benefits has been chaotic. Where in the United States, health insurance policies that did not meet minimum requirements were cancelled by regulators and the carriers themselves, leading, albeit with some consternation, to a more unified definition of EHB, in Israel a thousand market failure flowers have been left to bloom, although there have been some recent regulations introduced to quell this problem. Israel could learn something about putting teeth into health insurance regulation and governance.
Establishing and regulating EHB is a difficult challenge, and perhaps best viewed as part of a puzzle made up of pieces that come together in different ways in different health systems. From the comparison presented here, we can see that both the United States and Israel are involved in regulated competition, but in different ways based on different histories. Both countries are promoting universal health insurance, but with different levels of variation in coverage. Both systems are seeking to locate the locus of decision-making regarding EHB within their respective institutional structures. Pressure to imitate ‘best practices’ should be avoided, and replaced with thoughtful consideration of the pieces of the puzzle, and how to best assemble them in each health system under consideration. Even in the seemingly intractable world of EHB, exceptionalism can give way to productive cross country learning (Saltman and Figueras, Reference Rosenbaum, Frankford, Law and Rosenblatt1998).
